Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Asthma
Interventions: Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 71
States / cities: Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 118
States / cities: Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more

Conditions: Asthma
Interventions: Omalizumab, Inhaled Corticosteroid Boost Therapy (ICS), Placebo omalizumab, Placebo fluticasone; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Severe Asthma
Interventions: Frevecitinib, Placebo; Drug
Lead sponsor: Kinaset Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Lancaster, California • San Jose, California • Brandon, Florida + 11 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: olodaterol, tiotropium, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 809 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more

Conditions: COPD
Interventions: Umeclidinium / Vilanterol Dry Powder Inhaler, Placebo; Drug
Lead sponsor: Gary L. Pierce; Other
Eligibility: 30 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Albuterol sulfate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Asthma
Interventions: Albuterol Spiromax, ProAir HFA, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more

Conditions: Migraine With Aura, Migraine Without Aura
Interventions: Dronabinol MDI; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more

Conditions: Asthma
Interventions: Fluticasone furoate, Matching placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more

Conditions: Nicotine Dependence, Smoking Cessation
Interventions: Nicotrol Inhaler, Placebo Inhaler; Drug
Lead sponsor: UConn Health; Other
Eligibility: 16 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Hartford, Connecticut • Springfield, Massachusetts

Conditions: Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions: Haloperidol + lorazepam, Loxapine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Persistent Asthma
Interventions: Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 27
States / cities: Avondale, Arizona • North Hollywood, California • Bradenton, Florida + 21 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate/Vilanterol, Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more

Conditions: Asthma
Interventions: Vilanterol, Salmeterol Inhalation Powder, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder Diskus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Huntington Beach, California • Orlando, Florida • Tallahassee, Florida + 8 more

Conditions: Refractory or Unexplained Chronic Cough
Interventions: NOC-110, Placebo; Drug · Other
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 68
States / cities: Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more

Conditions: Asthma
Interventions: AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 21
States / cities: Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Stiolto Respimat, Placebo Respimat; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 45 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Asthma
Interventions: VR506, Placebo; Drug
Lead sponsor: Vectura Limited; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more

Conditions: Asthma
Interventions: Tiotropium low dose QD, Tiotropium high dose QD, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: Columbia, Missouri • Cincinnati, Ohio • Oklahoma City, Oklahoma + 3 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 300 μg, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Torrance, California • Lebanon, New Hampshire

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Search by objective public record fields.

Efficacy and Safety of Different Doses of Indacaterol

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations

A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients

(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Nicotine Replacement for Smoking Cessation During Pregnancy

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Study of Safety of Foradil in Patients With Persistent Asthma

A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy